Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

In multiple healthcare developments, Democratic states aim to safeguard Biden's rule for DACA immigrants, while ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...